Case Studies

Challenge: A Swiss biopharma company was developing a therapeutic for a severe orphan disorder. The company had successfully obtained Breakthrough Therapy Designation by the FDA and PRIME status by...

Challenge A biotech company focused on developing therapeutics for oncology indications was looking to contract a clinical consultant to support their in-house team in presenting its technology and...

Challenge An early stage, European cell therapy company focused on developing novel off-the-shelf NK cell therapy solutions for the treatment of a variety of cancers had developed a platform...

Challenge: Our client planning to develop and commercialize a preclinical compound for metabolic disorders. The product had a wide therapeutic potential for disorders associated with disruption of...

Challenge A start-up US biotech developing a non-opioid analgesic drug and delivery device was preparing to raise its first round of external funding. They engaged Alacrita to help frame the target...

Challenge: A biotech company focused on developing therapeutics for fibrotic diseases was looking at acquisitions or in-licensing as a way to grow its development pipeline with additional assets....

Challenge Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan...

Challenge A leading UK university and an executive agency of the DoH were collaboratively developing a rapid (30 min) bacterial ID and antimicrobial resistance test platform. The technology...

Challenge: Our client was a publicly-traded precision oncology company with whom Alacrita had previously supported with a long-term asset scouting engagement. This cash-rich biotech company wanted to...

Challenge: Our client was a US-based venture capital fund, with whom we have a long-standing retainer agreement to provide specialized due diligence support for their fund investment decisions. In...

Challenge: A pharmaceutical company with a proprietary clinical trial technology made the strategic decision to diversify their development arm by acquiring and/or in-licensing pharmaceutical...

Challenge: A client developing a repurposed drug for use in male fertility asked Alacrita to conduct a valuation for the asset in the US and EU4+UK in support of impending deal negotiations. The...